Effect of Sitagliptin on Progression of Coronary Intermediate Lesion
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT02655757
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 120 participants
- Sponsor
- Li Bo
- Registry
-
NCT02655757
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02655757. Randomized; no masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2017-02-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Sitagliptin on Progression of Coronary Intermediate Lesion
- Condition
- Atherosclerosis
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Li Bo
Record details
- Record id
cardio:ct-nct02655757- Content hash
3ddda7e8ef4b0502c8d8aa6a68462ced62ef9b02c79e1abfc766a46355e77404